Sinovac Adjourns 2008 Annual General Meeting

Saturday, September 19, 2009 General News J E 4
BEIJING, July 16 Sinovac Biotech Ltd. (NYSE Amex:SVA), a leading developer and provider of vaccines in China, announced todaythat its Annual General Meeting originally scheduled for July 16, 2009 hasbeen adjourned to July 30, 2009.

At the July 16, 2009 Annual General Meeting, the required quorum of amajority of the outstanding shares was not present. In accordance with Antigualaw, the meeting is adjourned to July 30, 2009 (the same day two weeks afterJuly 16, 2009), at 9 a.m. Beijing time at Sinovac's headquarters located at No.39, Shangdi Xi Rd., Haidian District, Beijing, PRC (the same time and place asthe originally scheduled meeting). Under Antigua law and in compliance withNYSE Amex Equities requirements, if a quorum is not present within thirtyminutes of the appointed time for holding the adjourned meeting, theshareholders then present representing at least one-third of the totaloutstanding shares will constitute a quorum.

The adjourned Annual General meeting will not affect Sinovac's normalcourse of business. We highly encourage our shareholders to submit their votesbefore July 30, 2009.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac'scommercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combinedhepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac iscurrently developing Universal Pandemic Influenza vaccine and Japaneseencephalitis vaccine. Additional information about Sinovac is available on itswebsite, . To be added to our distribution list, pleaseemail:

Safe Harbor Statement

This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that are nothistorical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update anyforward-looking statement, except as required under applicable law.For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: Investors: Amy Glynn/Sara Pellegrino The Ruth Group Tel: +1-646-536-7023/7002 Email: Media Janine McCargo The Ruth Group Tel: +1-656-536-7033 Email:

SOURCE Sinovac Biotech Ltd.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Blood Test Shows Statistically Significant Associa...
Raptor Pharmaceuticals Corp. to Present at 2009 Cy...